Communiqués de presse Archive - Page 18 of 21 - Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes

OSE Immunotherapeutics Presents CLEC-1

OSE Immunotherapeutics Announces COVID-19 Prophylactic Vaccine Program

OSE Immunotherapeutics Announces Positive Top-Line Results for Step-1 of its trial ‘Atalante 1’

OSE Immunotherapeutics Reports 2019 Financial Results

OSE Immunotherapeutics and Servier Amend the Global Licensing Option Agreement

OSE Immunotherapeutics Announces Collaboration with MAbSilico

OSE Immunotherapeutics Announces Issuance of a New Patent in Japan for Tedopi®

OSE Immunotherapeutics Announces Positive Results from Phase 1 Clinical Study of OSE-127

OSE Immunotherapeutics and HalioDx Collaborate to Perform Immune Biomarker Exploratory Work during Atalante 1 Phase 3

OSE Immunotherapeutics Presented Positive Correlation Between Neoepitope Response and Increased Survival for NSCLC Patients Treated with Tedopi®

Précédent
1
…
15
16
17
18
19
20
21
Suivant